Poolbeg Pharma has announced its FY 2024 results (for the period ending December 2024), alongside a conditional fundraise of approximately £4.1 million in gross proceeds through a placing, subscription, and retail open offer. The financing will be used to advance Poolbeg’s lead clinical asset into a Phase 2a study to investigate its application in the prevention of cytokine release syndrome (CRS) in relapsed refractory multiple myeloma patients receiving an approved bispecific antibody. Importan ....
